Skip to main content

Anti-SARS-CoV-2 Monoclonal Antibodies

By September 22, 2021Blog

By Don M. McNulty ~ Summary of NIH Covid-19 Treatment Guidelines
Released August 4, 2021

What is Monoclonal Antibody Treatment?

With all the Covid fears continuing to swirl around us today, we must stay on top of all the avenues of treatment afforded the American people. Crime Scene Cleaners who serve Missouri and Kansas for all things biohazard, including Covid cleaning and disinfection processes, are constantly searching for official clinical studies and research to pass along to the public to keep you well informed in this ever-changing environment about Covid infections and the variants.

The FDA Authorized the Emergency Use of the Anti-SARS-CoV-2 Monoclonal Antibody treatment. The treatment is intended for mild to moderate Covid-19 infections in nonhospitalized patients at high risk for progressing to severe disease and hospitalization.

There are two brands approved Casirivimab plus Imdevimab: These are recombinant human monoclonal antibodies that bind to non-overlapping epitopes of the spike protein RBD of SARS-CoV-2.

Sotrovimab: This monoclonal antibody was initially identified in 2003 from a SARS-CoV survivor. It targets an epitope in the RBD of the spike protein that is conserved between SARS-CoV and SARS-CoV-2.

The FDA also updated the EUA for Casirivimab plus Imdevimab as post-exposure prophylaxis for specific individuals who are at high risk of acquiring SARS-CoV-2 infection and, if infected, are at high risk of progressing to serious illness. See the for details.